Universal Health Services Inc (UHS)
Health Care · Health Care Facilities · US stock · S&P 500 component
$188.13
▲ +5.26 (2.88%)
Fair valueUndervalued
$287 +52.8% to fair value
$144fair band $245–$348$431
Day's range
$182.94 – $188.86
52-week range
$140.08 – $246.33
About Universal Health Services Inc
Universal Health Services operates hospitals and care facilities. Its acute care hospitals are located in the United States, and it runs a large behavioral health business with inpatient psychiatric hospitals and treatment centers in the United States and United Kingdom. Revenue comes from patient services paid by government programs, commercial insurers and individuals, so reimbursement rates and patient volumes matter.
Universal Health Services Inc generated $18.1 billion in revenue during the last twelve months. The three-year revenue growth rate is 9.0% a year. Operating margin stands at 11.4%, showing profit left after running costs. Return on invested capital stands at 13%. Net debt is 1.7 times of EBITDA. A dividend is paid, with a yield of 0.4%. The X-Ray Score is 66 out of 100.
Price chart
52-wk range $140.08 – $246.33Volume 489,111Daily, split-adjusted
Vitals
Market cap$11.3B
52-week range$140.08 – $246.33
Volume (last day)489,111
P/E (TTM)7.7
EBIT / EV yield12.8%
Free-cash-flow yield7.5%
Dividend yield0.4%
Revenue (TTM)$18.1B
Net income (TTM)$1.5B
Operating margin11.4%
Return on capital12.9%
Debt incl. leases$4.9B
Cash & securities$139M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$287middle half of models $261 – $332
Undervalued
+52.8% to fair value
Average of the 11 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is High, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $188
Undervalued < $245Fair $245 – $348Overvalued > $348
P/E multiple
$202
P/B multiple
$225
P/S multiple
$339
EV/EBITDA multiple
$297
EV/EBIT multiple
$306
EV/revenue multiple
$325
10-year DCF, EBITDA exit
$366
5-year DCF, EBITDA exit
$312
10-year DCF, revenue exit
$372
5-year DCF, revenue exit
$317
10-year DCF, growth exit · not used
$628
5-year DCF, growth exit · not used
$605
Dividend discount, stable · not used
$59
Dividend discount, multi-stage
$103
Earnings power value · not used
$602
Growth the price implies
-6.1%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Average business at a low price
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Strong
95/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield12.8%
Free-cash-flow yield7.5%
Fair value vs price1.5×
Growth
Strong
76/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)9.0%
EPS growth (3y)36.2%
Growth consistency100%
Profitability
Weak
45/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital12.9%
Operating margin11.4%
Financial health
Fair
63/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA1.7×
Interest cover13.1×
Dividends
Weak
31/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.4%
Dividends vs free cash flow6%
Dividend growth-4.3%
Quarterly results: last 6 quarters
+6.7%
Mar '25
+9.6%
Jun '25
+13.4%
Sep '25
+9.1%
Dec '25
+9.6%
Mar '26
+8.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $4.6B, diluted EPS $5.98.
Compare with peers
HCA HCA Healthcare, Inc.63Other Health Care Facilities companies by X-Ray Score.
SWOT analysis: Universal Health Services Inc
Strengthsinside the company
- Earnings per share have compounded at 36.2% a year over three years.
- Free cash flow equals 7.5% of the market value, which funds dividends, buybacks or debt paydown.
- Operating profit covers interest 13x, so debt costs are a small drag.
- Passes 8 of the 9 Piotroski tests, which points to improving profitability, funding and efficiency.
Weaknessesinside the company
- No clear weakness in the figures we track.
Opportunitiesvaluation and setting
- Trades at 7.4x earnings, 74% below the 28.4x median of sector peers.
- The price is 53% below our fair value estimate, with the gap larger than the margin we allow for error.
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- Valuation uncertainty is high: the models give widely different values, so the fair value range is wide.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare UHS with peers and sector
Medians of 59 Health Care peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): LLY 62, JNJ 49, ABBV 41, UNH 58, MRK 33, TMO 34.
| Metric | UHS | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 66 | 49 | 49 |
| Valuation | 95 | 52 | 52 |
| Growth | 76 | 47 | 47 |
| Profitability | 45 | 51 | 51 |
| Financial health | 63 | 48 | 48 |
| Dividends | 31 | 52 | 52 |
Sector leaders: highest X-Ray Score in Health Care
UHS ranks #10 of 60 in Health Care by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for UHS
Each factor is rated by where UHS stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 11 Good · 5 Average · 5 Bad of 21
Growth: 2 · 1 · 0
Profitability: 1 · 2 · 1
Financial strength: 1 · 2 · 1
Valuation: 5 · 0 · 0
Cash flow: 1 · 0 · 3
Efficiency: 1 · 0 · 0
| Factor | UHS | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | +9.0% | Good beats 68% | +5.5% | – | – |
| Revenue growth, last year | +9.7% | Average beats 66% | +7.1% | +9.4% | ≈ In line |
| EPS growth, 3 years a year | +36.2% | Good beats 84% | +5.0% | – | – |
| Profitability | |||||
| Operating margin | 11.4% | Bad beats 33% | 16.4% | 10.6% | ≈ In line |
| Net margin | 8.4% | Average beats 39% | 11.1% | 7.2% | ▲ Better |
| Return on invested capital | 12.9% | Average beats 56% | 12.2% | – | – |
| Return on equity | 20.3% | Good beats 69% | 13.7% | 16.3% | ▲ Better |
| Financial strength | |||||
| Net debt / EBITDA | 1.7x | Average beats 62% | 2.0x | 2.1x | ▲ Better |
| Interest cover | 13.1x | Average beats 53% | 9.4x | 9.0x | ▲ Better |
| Current ratio | 1.12 | Bad beats 21% | 1.52 | 1.27 | ▼ Worse |
| Piotroski F-score | 8 / 9 | Good beats 85% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 7.4x | Good beats 99% | 28.2x | 10.9x | ▲ Better |
| Price / book | 1.5x | Good beats 97% | 3.7x | 1.8x | ≈ In line |
| Price / sales | 0.6x | Good beats 86% | 3.7x | 0.8x | ≈ In line |
| EV / EBITDA | 5.9x | Good beats 99% | 17.6x | 7.9x | ▲ Better |
| Free cash flow yield | 7.5% | Good beats 86% | 4.4% | 4.9% | ▲ Better |
| Cash flow | |||||
| Free cash flow margin | 4.7% | Bad beats 20% | 16.3% | 3.7% | ≈ In line |
| Cash from operations / net income | 1.18 | Bad beats 19% | 1.61 | 1.47 | ▼ Worse |
| Free cash flow growth, 3 years a year | +48.0% | Good beats 93% | +4.3% | – | – |
| Accruals (lower is better) | −1.7% | Bad beats 15% | −3.9% | – | – |
| Efficiency | |||||
| Days sales outstanding | 56 days | Good beats 68% | 62 days | 55 days | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 8 Good · ● 3 Average · ● 3 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldGood
Risk models
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginBad
Each check is graded against the company's sector, not a fixed number. Checklist score 65/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $12.6B | $13.4B | $14.3B | $15.8B | $17.4B |
| Operating income | $1.4B | $1.0B | $1.2B | $1.7B | $2.0B |
| Net income | $992M | $676M | $718M | $1.1B | $1.5B |
| Operating cash flow | $884M | $996M | $1.3B | $2.1B | $1.9B |
| Operating margin | 10.8% | 7.5% | 8.2% | 10.6% | 11.5% |
| Free cash flow | $28M | $262M | $525M | $1.1B | $849M |
| Diluted EPS | $11.82 | $9.14 | $10.23 | $16.82 | $23.10 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
| SMA 10 | 183.2 | Bullish |
| EMA 10 | 183.3 | Bullish |
| SMA 20 | 179.7 | Bullish |
| EMA 20 | 180.9 | Bullish |
| SMA 50 | 176.3 | Bullish |
| EMA 50 | 176.0 | Bullish |
| SMA 100 | 165.0 | Bullish |
| EMA 100 | 173.4 | Bullish |
| SMA 200 | 177.4 | Bullish |
| EMA 200 | 176.7 | Bullish |
Oscillators (daily)
| RSI (14) | 63.21 | Neutral |
| MACD (12, 26) | 2.96 | Bullish |
| Momentum (12) | 6.24 | Bullish |
| Stochastic %K (14) | 85.90 | Bearish |
| Williams %R (14) | -14.10 | Bearish |
| CCI (20) | 117.0 | Bearish |
Pivot points (classic, last session)
S3 178.5 | S2 180.7 | S1 184.4 | Pivot 186.6 | R1 190.3 | R2 192.6 | R3 196.3 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.80 USD
Yield on today's price
0.43%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 | |
| 0.2000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold UHS
| ETF | Share of the fund |
|---|---|
| ASCE Allspring SMID Core | 1.81% |
| IHF iShares U.S. Healthcare Providers | 1.18% |
| FEGE First Eagle Global Equity | 0.85% |
| FFSM Fidelity Fundamental Small-Mid Cap | 0.49% |
| RPV Invesco S&P 500 Pure Value | 0.41% |
| DFAT DFA Investment Dimensions Group Inc. | 0.40% |
| DFSV DFA Investment Dimensions Group Inc. | 0.31% |
| RSP Invesco S&P 500 Equal Weight | 0.22% |
The eight funds with the largest weight in UHS among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
UHS stock splits
UHS has split its stock 3 times since 1996. The latest was a 2-for-1 split on 16 Dec 2009.
Full UHS stock split history →UHS SEC filings
8-KSEC EDGAR
Entered a material agreement
8-KSEC EDGAR
Other events
8-KSEC EDGAR
Entered a material agreement
424B5SEC EDGAR
424B5
424B5SEC EDGAR
424B5
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Entered a material agreement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.